Table 4.
ACCENT elderly 5-year recurrence-free survival rates (%) and Adjuvant! Online predictions assuming either “average for age” or “minor” comorbidities. Median predictions within corresponding Kaplan-Meier 95% confidence intervals and absolute differences less than 5% are shown in bold.
| N | K-M | 95% CI | Average for Age Comorbidities Assumed | Minor Comorbidities Assumed | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A!O Pred | Delta (O–E) | % Agree | Sens | Spec | A!O Pred | Delta (O–E) | % Agree | Sens | Spec | ||||
| Overall | 2967 | 58 | (56, 60) | 57 | 1 | 61 | 78 | 41 | 62 | −4 | 61 | 86 | 31 |
| Age | |||||||||||||
| 70–74 | 1944 | 59 | (57, 62) | 60 | −1 | 61 | 83 | 34 | 64 | −5 | 62 | 90 | 26 |
| 75+ | 1023 | 55 | (52, 58) | 52 | 3 | 61 | 68 | 54 | 58 | −3 | 59 | 79 | 38 |
| Sex | |||||||||||||
| Male | 1569 | 56 | (53, 58) | 55 | 1 | 58 | 71 | 45 | 61 | −5 | 58 | 84 | 31 |
| Female | 1398 | 60 | (58, 63) | 61 | −1 | 65 | 86 | 37 | 65 | −5 | 63 | 89 | 30 |
| TStage | |||||||||||||
| T1 | 83 | 77 | (68, 86) | 73 | 4 | 76 | 100 | 5 | 78 | −1 | 73 | 100 | 0 |
| T2 | 441 | 62 | (57, 66) | 67 | −5 | 61 | 97 | 10 | 73 | −11 | 60 | 99 | 6 |
| T3 | 2062 | 59 | (57, 61) | 57 | 2 | 60 | 77 | 40 | 61 | −2 | 60 | 86 | 28 |
| T4 | 381 | 43 | (38, 48) | 45 | −2 | 64 | 48 | 73 | 49 | −6 | 65 | 63 | 66 |
| Grade | |||||||||||||
| 1 | 278 | 60 | (54, 66) | 60 | 0 | 58 | 82 | 29 | 64 | −4 | 60 | 93 | 21 |
| 2 | 1950 | 59 | (57, 62) | 58 | 1 | 61 | 82 | 33 | 64 | −5 | 60 | 90 | 22 |
| 3+ | 739 | 53 | (50, 57) | 51 | 2 | 64 | 65 | 63 | 56 | −3 | 62 | 72 | 53 |
| + Node | |||||||||||||
| 1–3 | 1899 | 65 | (63, 67) | 62 | 3 | 62 | 91 | 17 | 66 | −1 | 63 | 97 | 8 |
| 4–10 | 937 | 48 | (44, 51) | 48 | 0 | 57 | 50 | 63 | 52 | −4 | 54 | 61 | 48 |
| > 10 | 131 | 27 | (20, 36) | 29 | −2 | 77 | 0 | 100 | 32 | −5 | 79 | 0 | 100 |
| # Node | |||||||||||||
| 1–3 | 127 | 58 | (50, 68) | 52 | 6 | 57 | 61 | 51 | 56 | 2 | 63 | 85 | 33 |
| 4–10 | 985 | 54 | (51, 58) | 56 | −2 | 60 | 74 | 45 | 61 | −7 | 59 | 84 | 34 |
| > 10 | 1855 | 60 | (57, 62) | 58 | 2 | 63 | 82 | 39 | 63 | −3 | 61 | 88 | 28 |
| Adj Rx | |||||||||||||
| 5FU/LV | 1814 | 55 | (53, 57) | 55 | 0 | 60 | 73 | 46 | 60 | −5 | 59 | 83 | 34 |
| + Ox | 1153 | 62 | (60, 65) | 61 | 1 | 63 | 87 | 33 | 65 | −3 | 63 | 93 | 23 |
| Decade | |||||||||||||
| 1980s | 211 | 45 | (38, 52) | 64 | −19 | 49 | 95 | 16 | 70 | −25 | 47 | 95 | 11 |
| 1990s | 1349 | 56 | (53, 59) | 54 | 2 | 61 | 71 | 51 | 59 | −3 | 61 | 81 | 39 |
| 2000s | 1407 | 62 | (59, 64) | 58 | 4 | 63 | 84 | 37 | 64 | −2 | 63 | 91 | 26 |
Abbreviations: TStage, tumor stage; +Node, positive nodes; # Node, nodes examined; Adj Rx, adjuvant chemotherapy; K-M, Kaplan-Meier; CI, confidence interval, Pred, median prediction; Diff, difference; O, observed; E, expected; Agree, agreement; Sens, sensitivity; Spec, specificity.